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Background: In subjects with hypercholesterolaemia, cholesterol values remain above guideline levels. One of the
limiting factors to the achievement of goals in such patients is therapeutic non-adherence. The aim of this study is to
assess the effectiveness of an intervention designed to improve control of hypercholesterolaemic patients, consisting
of a combined strategy that would include the delivery of printed information, treatment-compliance check cards and
the dispatch of text messages as complementary measures in support of the intervention at the general practitioner’s
practice.
Methods/Design: A randomised, parallel-group clinical trial will be conducted at the family medicine outpatient facilities
of eight health centres in three of Spain’s Autonomous Regions (Comunidades Autónomas), covering a total of 358 subjects
aged 18 years or over with diagnosis of hypercholesterolaemia. Patients in the intervention group will be supplied with
printed material with information on the disease and its management, mobile-telephone text messages with guideline
summaries, reminders of forthcoming appointments and/or arrangements for making new appointments in the event of
non-attendance, and self-report cards to check compliance with recommendations. Both groups -intervention and
control- will receive routine recommendations from their physicians in accordance with current European clinical practice
guidelines for hypercholesterolaemia and cardiovascular risk management. As regards the measurements to be made, the
main variable is the proportion of subjects who attain the low density lipoprotein cholesterol levels set as a target across a
follow-up period of 24 months. The secondary variables are as follows: adherence to recommendations on lifestyle and
adherence to drug treatment; variation in lipid profiles and cardiovascular risk levels; appearance of cardiovascular events;
physical activity; food consumption; smoking habit; anthropometric measures; blood pressure; health problems; use of
hypolipidaemic agents; socio-demographic data; beliefs and expectations about preventive recommendations; and degree
of satisfaction with the combined strategy.
Discussion: Should this intervention prove effective, a recommendation could be issued on the application of this
combined strategy to subjects with hypercholesterolaemia. It is a simple, relatively inexpensive intervention.
Trial registration: ClinicalTrials.gov: NCT02314663.
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Hypercholesterolaemia is one of the main cardiovascular
disease risk factors (CDRFs) and, according to different
studies undertaken in Spain, its prevalence in terms of
total plasma cholesterol concentrations of over 250 mg/dl,
extends to 20%-23% of the adult population [1,2].
The prevention and treatment of dyslipidaemia should
take the remaining CDRFs into account, with its man-
agement being based on the calculation of cardiovascular
risk. While most European clinical practice guidelines use
a Framingham or Systematic Coronary Risk Evaluation
(SCORE) function chart [3] for this purpose, the Registre
Gironí del Cor (REGICOR) study [4] offers an alternative,
using a series of tables adapted and validated in Spain.
Management of dyslipidaemia includes both pharmaco-
logical and non-pharmacological measures (diet and phys-
ical activity), with the latter being recommended for 3 to
6 months in primary prevention prior to the introduction
of hypolipidaemic treatment [5-7].
Furthermore, the degree of control of CVR (cardio-
vascular risk) factors is low, both in primary and in
secondary prevention. Despite guidelines and new hypo-
lipidaemic agents, the results of different studies none-
theless show that cholesterol values remain above
guideline targets [8]. Studies, such as HISPALIPID [9]
and PREVENCAT [10], have revealed poor control of
subjects with dyslipidaemia, with the designated targets
being attained in approximately 32% of cases. The
EUROASPIRE II study reported that 64% of patients
with coronary disease took hypolipidaemic agents, and
that approximately 53% failed to display adequate thera-
peutic control [8]. Similar results as regards achieve-
ment of goals were reported by the international
EUROASPIRE III [11] and LTAP-2 [12] studies, which
included data on Spain. Among the possible causes
of this situation are factors linked to hypolipidaemic
agents, adherence to prescribed treatment and phys-
ician-led prescription strategy.
Bearing in mind that over half of all patients with coron-
ary disease and over two thirds of subjects judged to be at
high cardiovascular risk fail to attain target lipid values
[13], it would seem necessary to implement strategies that
enhance adherence to lifestyle changes and compliance
with drug therapy. There is evidence of and wide consen-
sus about the benefits of the diet, exercise and drugs to be
used, both in primary prevention and in secondary pre-
vention in particular, for the purpose of achieving good
control of patients with hypercholesterolaemia.
Among the factors related to adherence to lifestyles
and drug therapy in dyslipidaemia, it should be noted
that the asymptomatic nature of this disease may con-
tribute to the poor results obtained [7]. Other possible
factors are an absence of perception of a risk to health
and negligible participation in decision-making [14].One of the limiting factors in the achievement of tar-
gets in hypercholesterolaemic patients is therapeutic
non-adherence, which decreases across time [15,16].
Moreover, such non-adherence should not be taken
to refer to medications exclusively, but also to the
remaining guidelines. In 2003 the World Health
Organization (WHO) defined the term adherence as,
“The extent to which a person’s behaviour - taking
medication, following a diet, and/or executing lifestyle
changes, corresponds with agreed recommendations
from a health care provider” [17]. Among dyslipedaemic
patients the percentage of non-compliers ranges from
22% to 57% [18], with different studies observing that,
in over half of all cases, this is due to forgetfulness when
it comes to taking the medication [19]. Other studies
have similarly reported a lack of compliance with life-
style recommendations [20].
Various strategies have been used to improve compli-
ance and, by extension, control of patients. The results
of the study conducted by Márquez et al. [21] into the
effectiveness of an isolated telephone intervention on
compliance with drug treatment, indicated better adher-
ence, yet the patients nevertheless displayed poor con-
trol of their dyslipidaemia. This may indicate that
improvement in pharmacological adherence alone is not
enough to attain designated targets, and that to achieve
adequate control, it is essential to follow recommenda-
tions other than those which are purely pharmaco-
logical. At present, evidence is not being transferred to
clinical practice, either here in Spain or in the rest of
Europe, and targets are thus not being achieved.
In addition, the strategies that have most improved
compliance among subjects with other risk factors, such
as hypertension, do not include specific activities, such
as pamphlets or telephone alerts, but rather combined
activities, such as group sessions coupled with mail-
based back-up and support [22], or alternatively, the de-
livery of printed matter, appointment-reminder tele-
phone calls and mail with educational messages about
the disease [23]. In this respect, there would seem to be
agreement on the need to use a combination of strat-
egies to improve adherence, thus surpassing the possible
benefits of single strategies implemented one at a time
[24,25]. Hence, studies that have used printed informa-
tion in tandem with individual health education [26,27]
have displayed better results than those that have evalu-
ated just one of these interventions [28,29], and have
successfully managed to increase knowledge about dys-
lipidaemia and its management. Likewise, strategies ex-
clusively targeted at recording the taking of medication,
e.g., telephone calls in the case of dyslipidaemias, have
achieved little improvement in compliance [30], with re-
sults showing improvement when different reminder
combinations have been used [31].
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pend on the population to be targeted and, when it comes
to choosing an intervention, consideration should be given
to the possible risk entailed in only implementing specific
actions that have no continuity and are excessively costly
(in terms of time or money) for the expected benefit [32].
In the light of the above, we therefore propose a com-
bined strategy to improve compliance with the recom-
mendations contained in clinical practice guidelines for
management of dyslipidaemia, both as to lifestyles (diet,
physical activity, alcohol and loss of weight) and as to
hypolipidaemic agents. It is a strategy targeted at
improving knowledge of dyslipidaemia, increasing com-
pliance with recommendations and facilitating greater
patient participation. To this end, a controlled study
should be undertaken to examine the effectiveness of
such a strategy in terms of adherence to recommenda-
tions and control of the cholesterol values of subjects
with hypercholesterolaemia.
The proposed study follows the recommendations
made by Haynes [33] for studies that assess compliance
strategies, inasmuch as it investigates an easily applicable
practical intervention, uses a randomised-clinical-trial
design, and envisages measuring both therapeutic adher-
ence and the degree of lipid control achieved.
Study objectives
The main aim of this study is to assess the effectiveness of
an intervention designed to improve control of hypercho-
lesterolaemic patients, consisting of a combined strategy
that would include the delivery of printed information,
text messages and treatment-compliance check cards as
complementary measures in support of the intervention at
the general practitioner’s (GP) practice.
The secondary objectives would be: 1) to ascertain
whether, with respect to routine GP care, the combined
intervention strategy improves therapeutic adherence,
both pharmacological and non-pharmacological, of hy-
percholesterolaemic patients, across a follow-up period
of 24 months; 2) to ascertain whether, with respect to
routine GP care, the combined intervention strategy
increases the proportion of patients who attain the low
density lipoprotein cholesterol (LDL-C) values set
for adequate control, across a follow-up period of
24 months; 3) to quantify the effect of the combined
intervention strategy on the remaining lipid-profile-
defining parameters, across follow-up; 4) to quantify the
effect of the combined strategy on the reduction of car-
diovascular risk in patients with hypercholesterolaemia,
across follow-up; 5) to identify the factors that contrib-
ute to improving the effectiveness of the combined
intervention strategy on reducing lipid values, not only
in relation to patients’ health status but also in relation
to their socio-demographic variables; and, 6) to assessthe acceptance and degree of satisfaction of the hyper-
cholesterolaemic patients undergoing the intervention.
Methods/Design
Design
Randomised, parallel-group clinical trial in which a group
of hypercholesterolaemic patients, undergoing a combined
intervention targeted at improving treatment adherence
and degree of lipid control as complementary measures in
support of the intervention at the GP’s practice, will be
compared to another group of hypercholesterolaemic pa-
tients who will solely receive routine GP care.
Study location and subjects
Participants will be recruited from among patients
attending family medicine outpatient facilities at 8
health centres situated in three health areas of three of
Spain’s Autonomous Regions (Comunidades Autóno-
mas), namely, Castile-La Mancha (Albacete Health
Area), Aragon (Zaragoza Health Area) and Galicia (Vigo
Health Area). The target population is made up of all
persons aged 18 years or over with diagnosis of hyper-
cholesterolaemia, with the population eligible for study
comprising hypercholesterolaemic subjects of this age
drawn from the eight health centres in the above three
participating health areas.
The study inclusion criteria require that candidates: a)
be diagnosed with hypercholesterolaemia, as defined ac-
cording to the criteria stipulated in the cardiovascular
prevention guidelines of the 2009 Prevention Activities
and Promotion of Health Programme (total cholesterol
of 250 mg/dl or higher); and, b) be patients aged 18 years
or over attending any of the participating health centres.
The following individuals will be excluded: a) any person
hindered from participating in the follow-up of the pro-
posed intervention, e.g., illiterate subjects and non-users
of mobile telephones; b) any person with a physical dis-
ability or impairment which prevents him/her from at-
tending the follow-up visits; and, c) any person suffering
from a significant chronic organic or psychiatric disease.
Sample size
The sample size needed for analysis will be calculated
using a two-sided test, based a clinically relevant differ-
ence of 20% in the proportion of subjects who attain the
lipid control targets, i.e., 55% in the control group, ac-
cording to data furnished by previous studies (Kotseva
et al. [8,11]; Bueno et al. [18]), and 75% in the group
undergoing the proposed intervention. Assuming a stat-
istical power of 90% and an α error of 5%, the estimated
sample size would then be 155 subjects in each group
(total of 310 subjects). Assuming an expected proportion
of losses of 15%, the final size of each group would be
179 subjects (an overall total of 358).
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Eight health centres in the Albacete, Zaragoza and Vigo
Health Areas have been chosen for strategic reasons. To
prevent contamination bias, the control group participants
will belong to areas different to those of the experimental
groups. Accordingly, participants will be randomised on a
health-area basis, with subjects then being consecutively
selected.
Intervention
Participants in the intervention group will be supplied with:
a) printed matter containing information on the disease and
its management (this will be handed out at each of the
follow-up visits); b) mobile-telephone text messages contain-
ing guideline summaries, reminders of forthcoming appoint-
ments and/or arrangements for making new appointments
in the event of non-attendance (in the periods between
visits); and, c) self-report cards to check compliance with
recommendations (across the entire follow-up).
Both groups, intervention and control, will receive rou-
tine recommendations from their GPs, in accordance with
current European clinical practice guidelines on the man-
agement of hypercholesterolaemia and cardiovascular risk
(European Guidelines on Cardiovascular Disease Preven-
tion in Clinical Practice: Fifth Joint Task Force of the
European Society of Cardiology and other societies and
Guidelines for Management of Dyslipidaemias: the Task
Force for the Management of Dyslipidaemias of the
European Society of Cardiology and the European Athero-
sclerosis Society).
Subject follow-up
Subjects will be monitored for a period of two years.
Selection will be made at primary care outpatient facil-
ities, inviting patients who meet the inclusion criteria to
participate in the study. Once they have given their con-
sent, such patients will then be given an appointment for
an initial visit and analysis.
During the initial visit, patients will be randomised to
one of the two groups. Data will be collected from all par-
ticipants covering medical history (socio-demographic
variables, personal and family background, lifestyle habits),
physical examination (anthropometric parameters, blood
pressure), analysis (lipid profile, glucose) and calculation
of cardiovascular risk. The routine standard recommenda-
tions, pharmacological and non-pharmacological, will be
made for their treatment. An appointment will be made
for the next visit.
Participants included in the intervention group will be
given printed matter describing the disease and its manage-
ment, along with treatment-compliance check cards, and
they will be informed about the frequency and content of
the mobile-telephone text messages that they will receive.
Disease-management reminders will be dispatched every15 days and reminders about attendance at pending ap-
pointments or missed appointments will be sent according
to the follow-up dates.
With respect to follow-up, after the initial visit, 5 more
will be made: these will take place at 2, 6, 12, 18, and
24 months. At each of these visits, anthropometric parame-
ters (weight, BMI and waist circumference), blood pressure
figures, lipid profile (total cholesterol, LDL-C, HDL-C and
triglycerides), glucose and clinical history data will be
recorded, and cardiovascular risk will be calculated. Data
evaluating compliance with or adherence to treatment
guidelines will be obtained for both groups of patients. Data
on satisfaction will solely be recorded during the final visit,
and then only for subjects in the intervention group.
Any of the following circumstances will be grounds for
termination of the study in the case of any given partici-
pant: completion of the observation period (2 years); vio-
lation of the protocol; intercurrent disease that renders
continuation of the intervention impossible; and with-
drawal from the study/withdrawal of consent.
Definitions of the primary variables and measuring
methods
The main study variable is the proportion of subjects
who attain the LDL-C levels set as targets by the Guide-
lines for Management of Dyslipidaemias and CVR,
across a follow-up period of 24 months. The plasma
values taken as cardiovascular prevention targets are: a)
LDL-C <100 mg/dl for patients without established car-
diovascular disease or diabetes mellitus; and, b) LDL-C
<70 mg/dl for patients with diabetes mellitus or estab-
lished cardiovascular disease.
The secondary variables are as follows:
– adherence to lifestyle guidelines and adherence to
drug treatment, as seen from self-reported adher-
ence (adapted Haynes-Sackett test), validated ques-
tionnaire (Morisky-Green test) and Likert scale with 5
response options;
– variation in plasma lipid profile levels at 2, 6, 12, 18
and 24 months (total cholesterol, LDL-C, HDL-C
and triglycerides);
– variation in cardiovascular risk level across follow-
up, with assessment to be performed using the
SCORE (low CVR countries) and REGICOR tables;
– appearance of cardiovascular events in the
observation period, i.e., ischaemic heart disease,
atherothrombotic cerebrovascular disease, heart
failure and peripheral arterial disease;
– physical activity, i.e., determination of the degree of
aerobic physical exercise performed (active, partially
active or inactive);
– determination of the frequency of food
consumption;
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anyone who answers affirmatively to the question,
“Do you smoke?”;
– anthropometric measures, i.e., weight, height, body
mass index (BMI), and waist circumference;
– systolic and diastolic blood pressure (two
measurements), with the result being the mean of
the two results;
– health problems (WONCA ICPC-2 classification)
and drug use;
– use of hypolipidaemic drug treatment (type of drug
and dose);
– socio-demographic data, including age, sex, marital
status, educational level and social class;
– beliefs and expectations about preventive
recommendations: fulfilment of initial expectations
in terms of improvement obtained and related
drawbacks (questions with 5 Likert-type response
options ranging from 1 “much more than expected”
to 5 “much less than expected”); and,
– degree of satisfaction with the combined strategy
according to a satisfaction questionnaire (Likert
scale with 5 response options ranging from 1 “very
dissatisfied” to 5 “very satisfied”).
Statistical analysis
We will compare the variables of interest and the stratifi-
cation and potentially confounding variables at baseline in
both groups. The homogeneity of the two groups will be
ascertained in terms of the baseline values of the study
variables (Student’s t and chi-squared test, depending on
the nature of the variables).
The subjects in the two groups will be classified into dif-
ferent LDL-C and total cholesterol reduction levels, and an
initial crude analysis will be performed to assess the follow-
ing parameters together with their respective 95% confi-
dence intervals (CIs): absolute benefit increase (ABI);
relative benefit increase (RBI); and number needed to treat
(NNT).
Incidence of the outcome variables will be described
and compared (proportion of subjects with appropriate
control of lipid parameters and proportion of those who
were guideline compliers) in both groups for each
follow-up period (tests of comparison of proportions:
Chi-squared test). Comparison of variations in lipid pro-
files in each group across the study will be made using
the Student’s T-test or its non-parametric alternative
(Mann–Whitney U test); and changes in the parameters
in each group will be analysed using the T-test for re-
peated measures.
The possible existence of confounding factors or
interaction of other variables in the relationship be-
tween the proposed intervention and the outcome vari-
ables will be assessed with the aid of logistic regressionmodels (dependent variables: control of lipid parameters
and therapeutic adherence). For continuous variables, as-
sessment will be made using multiple linear regression.
Analysis will be conducted on an intention-to-treat
basis, with all randomised patients being included in the
analysis of effectiveness in accordance with their rando-
mised group, regardless of the intervention received. In
addition, a protocol analysis will also be performed for the
main variables.
All analyses will be performed using the SPSS v20.0.
computer software programme.
Ethics approval
This study was approved by the Clinical Research Ethics
Committee of the Albacete University Teaching Hospital
on 27 March 2012. All participants signed the informed
consent form to participate in the study.
Discussion
Finding a type of action that could yield a higher success
rate in the compliance and control of subjects with hyper-
cholesterolaemia is fundamental when it comes to opti-
mising available resources and improving the prevention
and treatment of cardiovascular disease. This is why we
feel that the most effective strategy will have to include ac-
tivities targeted at enhancing knowledge about dyslipidae-
mia, reminding patients about guidelines and facilitating a
higher patient participation rate. Similarly, we propose an
action that is targeted, not only at pharmacological adher-
ence, but also at the remaining recommendations for im-
proving control of hypercholesterolaemia.
The results of the study will provide extremely useful
information about the effectiveness of the proposed
strategy of improving compliance in the prevention and
management of cardiovascular disease based on in-
creased control of lipid profile plasma levels. Should this
intervention prove effective, a recommendation could
then be issued on the application of the combined strat-
egy to subjects with hypercholesterolaemia. Since it is a
simple and relatively inexpensive intervention, it could
be included as a recommendation in the respective clin-
ical practice guidelines.
Selection biases will be reduced by using a randomisa-
tion procedure because it is not the researcher who allo-
cates the intervention, and so any factor that might
influence participation would affect both groups to the
same degree. Likewise, confounding bias will be reduced
by the effect of random chance, as a result of which any
determinants that might influence the final result will tend
to be shared between the intervention and control groups.
There is the possibility that the sample may not be rep-
resentative of all eligible subjects, owing to differences be-
tween the persons who agree and those who do not agree
to participate, posing a problem of external validity if the
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who agree to participate in the study may possibly be more
predisposed to follow guidelines than are the remaining
candidates.
There could be a bias in data-collection due to the effect
of regression towards the mean, applicable to analytical re-
sults. There is also the possibility of a risk of differential
losses in follow-up between the groups compared, due to
the duration of the study.
With the help of the health professionals who usually
attend to the patients, every effort will be made to the
reduce the number of losses to follow-up. Even so, in a
case where such losses proved to be high and were not
caused at random, a bias could appear in the measure-
ments and compromise the study’s validity, due to the
low representativeness of the sample.
The intervention proposal (combined strategy of improv-
ing adherence) does not allow for application of masking
techniques, with only blind evaluation of results being
feasible.
In view of the fact that the study is to be undertaken at
various health centres in different Autonomous Regions,
possible sources of error and their respective control mech-
anisms might be: protocol deviations (appropriate staff
training will be undertaken); and data errors or omissions
(these will be minimised using techniques for identifying
anomalous data, and regular reports).
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